{"output": [["Acceleron Pharma Inc.", "COMP", "Operate_In", "Cambridge", "GPE"], ["Acceleron Pharma Inc.", "COMP", "Introduce", "Matthew L. Sherman", "PERSON"], ["Matthew L. Sherman", "PERSON", "Retire", "", ""], ["Matthew L. Sherman", "PERSON", "Relate_To", "MEDALIST and BELIEVE Phase 3 clinical trials", "EVENT"], ["MEDALIST and BELIEVE Phase 3 clinical trials", "EVENT", "Occur", "Middle of this year", "TIME"], ["Acceleron Pharma Inc.", "COMP", "Collaborate_With", "Celgene Corporation", "COMP"], ["Acceleron Pharma Inc.", "COMP", "Develop", "luspatercept", "PRODUCT"], ["Celgene Corporation", "COMP", "Develop", "luspatercept", "PRODUCT"], ["Acceleron Pharma Inc.", "COMP", "Has", "Lead program", "CONCEPT"], ["Acceleron Pharma Inc.", "COMP", "Develop", "Chronic anemia in hematologic disorders", "CONCEPT"], ["Matthew L. Sherman", "PERSON", "Lead", "Clinical development of multiple internally discovered programs", "CONCEPT"], ["Matthew L. Sherman", "PERSON", "Lead", "Phase 1 and Phase 2 clinical trials of luspatercept", "EVENT"], ["Habib Dable", "PERSON", "Be", "President and Chief Executive Officer of Acceleron", "ORG"], ["Habib Dable", "PERSON", "Grateful", "Matthew L. Sherman", "PERSON"], ["Habib Dable", "PERSON", "Benefit", "Matthew L. Sherman\u2019s expertise", "CONCEPT"], ["Acceleron Pharma Inc.", "COMP", "Anticipate", "Process for regulatory approval of luspatercept", "CONCEPT"], ["Matthew L. Sherman", "PERSON", "Remain", "", ""], ["Matthew L. Sherman", "PERSON", "Serve", "Advisory capacity for one year", "CONCEPT"], ["Acceleron Pharma Inc.", "COMP", "Initiate", "Search for the position of Chief Medical Officer", "CONCEPT"], ["Acceleron Pharma Inc.", "COMP", "Focus", "Research and development efforts in hematologic, neuromuscular, and pulmonary diseases", "CONCEPT"], ["Acceleron Pharma Inc.", "COMP", "Develop", "Luspatercept for the treatment of chronic anemia in myelodysplastic syndromes", "CONCEPT"], ["Acceleron Pharma Inc.", "COMP", "Develop", "Luspatercept for the treatment of chronic anemia in beta-thalassemia", "CONCEPT"], ["Acceleron Pharma Inc.", "COMP", "Develop", "Luspatercept for the treatment of chronic anemia in myelofibrosis", "CONCEPT"], ["Acceleron Pharma Inc.", "COMP", "Advance", "Neuromuscular franchise with two distinct Myostatin+ agents", "CONCEPT"], ["Acceleron Pharma Inc.", "COMP", "Advance", "Pulmonary program with a Phase 2 trial of sotatercept planned in pulmonary arterial hypertension", "CONCEPT"], ["Acceleron Pharma Inc.", "COMP", "Have", "Website", "CONCEPT"], ["Acceleron Pharma Inc.", "COMP", "Have", "Social media account", "CONCEPT"], ["Company", "ORG", "Make", "Filings with the SEC", "CONCEPT"], ["Company", "ORG", "Identify", "Risk factors", "CONCEPT"], ["Company", "ORG", "Disclaim", "Obligation to update any forward-looking statements", "CONCEPT"]], "published": "2018-01-03T15:00:00.000+02:00"}